A Multicenter Phase I/II Clinical Study on Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 08 Sep 2023
At a glance
- Drugs CT 120 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Nanjing IASO Biotechnology; Nanjing IASO Biotherapeutics
- 28 Oct 2021 New trial record